Vascular Biology, Atherosclerosis, and Endothelium Biology

Topical Simvastatin Accelerates Wound Healing in Diabetes by Enhancing Angiogenesis and Lymphangiogenesis

Jun Asai,* Hideya Takenaka,* Satoshi Hirakawa,† Jun-ichi Sakabe,† Asami Hagura,* Saburo Kishimoto,* Kazuichi Maruyama,‡ Kentaro Kajiya,§ Shigeru Kinoshita,‡ Yoshiki Tokura,† and Norito Katoh*

From the Departments of Dermatology* and Ophthalmology† and Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto; the Department of Dermatology,† Hamamatsu University School of Medicine, Hamamatsu; and the Shiseido Innovative Science Research Center,§ Yokohama, Japan

Impaired wound healing is a major complication of diabetes. Recent studies have reported reduced lymphangiogenesis and angiogenesis during diabetic wound healing, which are thought to be new therapeutic targets. Statins have effects beyond cholesterol reduction and can stimulate angiogenesis when used systemically. However, the effects of topically applied statins on wound healing have not been well investigated. The present study tested the hypothesis that topical application of simvastatin would promote lymphangiogenesis and angiogenesis during wound healing in genetically diabetic mice. A full-thickness skin wound was generated on the back of the diabetic mice and treated with simvastatin or vehicle topically. Simvastatin administration resulted in significant acceleration of wound recovery, which was notable for increases in both angiogenesis and lymphangiogenesis. Furthermore, simvastatin promoted infiltration of macrophages, which produced vascular endothelial growth factor C in granulation tissues. In vitro, simvastatin directly promoted capillary morphogenesis and exerted an antiapoptotic effect on lymphatic endothelial cells. These results suggest that the favorable effects of simvastatin on lymphangiogenesis are due to both a direct influence on lymphatics and indirect effects via macrophages homing to the wound. In conclusion, a simple strategy of topically applied simvastatin may have significant therapeutic potential for enhanced wound healing in patients with impaired microcirculation such as that in diabetes. (Am J Pathol 2012, 181:2217–2224; http://dx.doi.org/10.1016/j.ajpath.2012.08.023)

Delayed wound healing is a major complication of diabetes and is caused by increased apoptosis, delayed cellular infiltration, reduced angiogenesis, and decreased formation and organization of collagen fibers.1–3 Impaired lymphangiogenesis has also recently been established as a major factor in diabetic refractory wound healing.4,5 The functions of lymphatic vessels in wounds are to drain the protein-rich lymph from the extracellular space, to maintain normal tissue pressure, and to mediate the immune response.6,7 Delayed wound healing, such as that seen in infections, appears to result from persistent edema and delayed removal of debris and inflammatory cells due to reduced lymphatic development.8 Statins are HMG-CoA (5-hydroxy-3-methylglutaryl-coenzyme A) reductase inhibitors that are primarily used to lower circulating cholesterol levels. In addition, statins have been found to protect against ischemic injury and stimulate angiogenesis in normocholesterolemic animals.9–11 This angiogenic effect is partially mediated by direct regulation of proliferation of endothelial cells and capillary morphogenesis via the Akt/Pi3K pathway.11 Simvastatin has been found to enhance vascular endothelial growth factor (VEGF) production and improve wound healing in an experimental model of diabetes,12 and nitropravastatin stimulates reparative neovascularization and improves recovery from limb ischemia in type 1 diabetic mice.13 However, systemic administration at an extremely high dose was used to obtain angiogenic effects in...
these studies, and this is inapplicable for clinical use as an angiogenic drug in patients with ischemic disorders. However, topical application of statins with avoidance of systemic adverse effects may be useful for cutaneous wound healing, in which angiogenesis plays a pivotal role. The lymphangiogenic effects of statins have not been widely investigated. In this study, we evaluated the effects of topical simvastatin on angiogenesis and lymphangiogenesis in a mouse model of impaired diabetic wound healing.

Materials and Methods

Animals

Genetically diabetic C57BLKS/J-m+/+Lepr<sup>db</sup> mice (db/db mice) were obtained from Clea Japan, Inc. (Tokyo, Japan). All procedures were performed in accordance with the guidelines of the Animal Care and Use Committees of Kyoto Prefectural University of Medicine.

Creation of Wounds

Mice were between 6 and 10 weeks old at the time of the study. Wounds were generated as described previously. In brief, after induction of deep anesthesia by i.p. injection of sodium pentobarbital (160 mg/kg), full-thickness, excisional skin wounds using 8-mm skin biopsy punches were made on the backs of mice, with one wound generated in each mouse. Each wound was covered with a semipermeable polyurethane dressing (OpSite; Smith and Nephew, Massillon, OH) after topical application of simvastatin (Calbiochem, La Jolla, CA) in petroleum jelly (a mixture of 5 mg of simvastatin and 995 mg of jelly) or vehicle (petroleum jelly alone). Simvastatin in petroleum jelly (10 mg of the mixture containing 50 μg of simvastatin) or vehicle were applied to the wound on days 0, 4, 7, and 10 after creation of the wound.

Monitoring of Wound Healing

A total of 5 db/db mice were used at each time point. Wound healing was monitored by taking pictures with a digital camera (Nikon Coolpix 995; Nikon, Tokyo, Japan) on days 0, 4, 7, and 14 after wound creation. Images were analyzed using ImageJ software version 1.46 (NIH, Bethesda, MD) by tracing the wound margin with a high-resolution computer mouse and calculating the pixel area. Wound closure was calculated as follows: Percentage Closed = [(Area on Day 0 – Open Area on Final Day)/Area on Day 0] × 100, as described previously. The areas of the wounds were compared with Student’s t-test with P < 0.05 taken to indicate a significant difference.

Histologic Score

A histologic score was assigned in a masked manner as described previously. Briefly, each specimen received a score of 1 to 12 as follows: 1 to 3, none to minimal cell accumulation and granulation tissue or epithelial migration; 4 to 6, thin, immature granulation dominated by inflammatory cells but with few fibroblasts, capillaries, or collagen deposition and minimal epithelial migration; 7 to 9, moderately thick granulation tissue, ranging from mainly inflammatory cells to more fibroblasts and collagen deposition; and 10 to 12, thick, vascular granulation tissue dominated by fibroblasts and extensive collagen deposition.

Evaluation of Wound Angiogenesis and Lymphangiogenesis

Sections were stained with rat anti-CD31 antibody (1:100) (BD Biosciences, San Jose, CA) or rabbit anti-LYVE-1 antibody (Upstate, Lake Placid, NY). Green fluorescence was generated by labeling with fluorescein isothiocyanate (FITC)–streptavidin (Vector Laboratories, Burlingame, CA) and biotinylated anti-rat or anti-rabbit antibody (both Vector Laboratories). Wound angiogenesis or lymphangiogenesis was analyzed by calculating the percentage of fluorescent area. Briefly, for each slide, an image of the granulation tissue at the wound margin was captured. ImageJ software was used to quantitate the fluorescence intensity. The mean percentage of fluorescent pixels of five images served as an index of the angiogenic or lymphangiogenic response.

Evaluation of Macrophage Number, Phenotype, and VEGF-C Expression in Granulation Tissue

Sections of wounds were stained with rat anti-F4/80 antibody (Invitrogen, Carlsbad, CA). Labeling with F4/80 was visualized with Cy3-conjugated anti-rat antibody (Vector Laboratories). Ten granulation tissue fields (two sections from each animal) were selected, and F4/80-positive cells were counted. VEGF-C expression was evaluated using goat anti-VEGF-C antibody (Santa Cruz Biotechnology, Santa Cruz, CA) and FITC-conjugated anti-goat antibody (Vector Laboratories). To determine the phenotype of infiltrating macrophages, IL-13 and tumor necrosis factor (TNF) α expression was evaluated using goat anti-IL-13 antibody and goat anti-TNF-α antibody (Santa Cruz Biotechnology, Santa Cruz, CA), respectively, and FITC-conjugated anti-goat antibody. F4/80-positive TNF-α-positive cells were defined as an M1 phenotype and F4/80-positive IL-13-positive cells as an M2 phenotype. In each slide, F4/80-positive cells, F4/80-positive TNF-α-positive cells, and F4/80-positive IL-13-positive cells were counted, and percentages of TNF-α-positive macrophages and IL-13-positive macrophages were evaluated. The mean percentages of TNF-α-positive macrophages and IL-13-positive macrophages in five images were used as indexes of the M1 and M2 phenotypes, respectively.

RNA Isolation, cDNA Synthesis, and Quantitative RT-PCR

Tissue sections obtained in RNAlater (Ambion, Paisley, UK) were processed for RNA isolation, cDNA synthesis, and quantitative RT-PCR. VEGF-C, fibroblast growth factor 2, endothelial nitric oxide synthase, stromal cell-derived factor 1α, and platelet-derived growth factor β gene expression levels were normalized based on the level of an internal
reference gene, 18S. The primers used in the study were obtained from QIAGEN (Düsseldorf, Germany).

**Cell Culture**

Primary human lymphatic endothelial cells (LECs) were collected as previously described. LECs were cultured at 37°C in 5% CO₂ in endothelial cell basal medium 2 (Lonza, Walkersville, MD) supplemented with 5% fetal bovine serum, human VEGF-A, human fibroblast growth factor 2, human epidermal growth factor, insulin-like growth factor 1, and ascorbic acid. Each experiment was conducted at least three times, with similar results. A representative experiment is shown.

**Western Blot Analysis**

Cells were lysed with RIPA buffer (Invitrogen) and sonicated. After sonication, cell lysates were centrifuged at 15,400 x g for 20 minutes at 4°C, and the supernatants were collected into fresh tubes. Then 4 x 10⁶ SDS sample buffer with 0.1 mol/L dithiothreitol was added to samples. Samples were boiled for 5 minutes at 95°C, and 20-μg extracts were separated by 10% SDS-PAGE and electroblotted onto polyvinylidene difluoride membranes for 2 hours at 180 mA. The membranes were incubated with rabbit anti-human Akt (pan) (C67E7) monoclonal antibody (Cell Signaling Technology, Danvers, MA), rabbit anti-human phospho-Akt (Ser473) (D9E) monoclonal antibody (Cell Signaling Technology), or mouse anti-GAPDH monoclonal antibody (Santa Cruz Biotechnology) and detected with horseradish peroxidase–conjugated goat anti-rabbit IgG (Bio-Rad, Hercules, CA) or horseradish peroxidase–conjugated goat anti-mouse IgG (Bio-Rad). Immunoblots were visualized using an ECL Plus Western Blotting Detection Reagents Kit (GE Healthcare, Little Chalfont, Buckinghamshire, UK) according to the manufacturer protocol.

**Chord Formation Assay**

LECs were used in a chord formation assay. An aliquot (100 μL) of growth factor–depleted Matrigel (Becton Dickeson, Bedford, MA) was added to a 24-well dish and allowed to gel for 30 minutes at 37°C. LECs were seeded at 5 x 10⁴ cells/mL in 500 μL of endothelial cell basal medium 2 containing 3% fetal bovine serum. Cells were cultured in the absence or presence of various doses of simvastatin (Calbiochem, Darmstadt, Germany) with or without pretreatment with a PI3 kinase inhibitor, LY294002 (50 μmol/L) (ENZO Life Sciences, Plymouth Meeting, PA), the mTOR/raptor inhibitor rapamycin (100 nmol/L) (Merck Millipore, Darmstadt, Germany), or the PI3K/mTOR inhibitor wortmannin-rapamycin (100 nmol/L) (Cayman Chemical, Ann Arbor, MI) for 30 minutes. Chord formation was monitored for 24 hours. Digital pictures were taken using a spot image analysis system, and the total length of the chord-like structures at 12 hours was outlined and measured using ImageJ software.

**Proliferation Assay**

The proliferative activity of cells treated with simvastatin was examined using a CellTiter 96 nonradioactive cell proliferation assay (Promega, Madison, WI). Briefly, subconfluent cells (5000 cells per well) were reseeded on 96-well, flat-bottomed plates with 100 μL of growth media. The cells were treated with simvastatin and incubated for 48 hours at 37°C. Absorbance at 570 nm was recorded using a 96-well enzyme-linked immunosorbent assay (ELISA) plate reader.

**Apoptosis Assay**

An apoptosis assay was performed using a DeadEnd Fluorometric TUNEL System (Promega). Briefly, LECs were plated on chamber slides and placed in medium. Cells were stimulated by simvastatin and incubated for 24 hours with medium containing 400 μmol/L H₂O₂. To quantify apoptosis, 400 nuclei from random microscopic fields were analyzed by an observer masked to the treatment groups. The number of apoptotic cells was expressed as a percentage of the total cell count.

![Figure 1](https://example.com/image.png)

**Figure 1.** Effects of topical simvastatin on wound closure and histologic score in db/db mice. A: Representative macroscopic views of wounds after different treatments and periods. Scale bar = 2 mm. Arrows indicate the epithelialized range. B: Wound closure was measured on days 4, 7, and 14. *P < 0.05, **P < 0.001 versus vehicle (n = 5 in each group). C: Histologic scores for days 4, 7, and 14, quantified as described in Materials and Methods. Higher histologic scores indicate a greater extent of wound healing. *P < 0.05 versus vehicle (n = 5 in each group).
Statistical Analysis

All results are presented as mean ± SEM. Statistical comparisons between two groups were performed by Student’s t-test. Multiple groups were analyzed by one-way analysis of variance followed by appropriate post hoc tests to determine statistical significance. P < 0.05 was considered significant. All in vitro experiments were performed at least in triplicate.

Results

Simvastatin Accelerates Wound Healing in Diabetic Mice

Wound areas on days 7 and 14 in simvastatin- or vehicle-treated diabetic mice are shown in Figure 1A. On day 14, simvastatin-treated wounds had more than 90% epithelialization, whereas <80% of the wound was epithelialized in the vehicle-treated group (Figure 1B). Simvastatin treatment resulted in significantly smaller wound areas after 4, 7, and 14 days. The difference in percentage of wound closure reached a maximum on day 7 (simvastatin versus control: 79.26% ± 11.09% versus 52.45% ± 16.81%; P < 0.001). The histologic score reflects the degree of maturation of granulation tissue, including inflammation, collagen deposition, and reepithelialization, in addition to neovascularization; therefore, higher histologic scores reflect a greater extent of wound healing. The histologic scores for wounds treated with simvastatin were significantly higher than those in the vehicle-treated group (day 4: 3.6 ± 0.70 versus 1.9 ± 0.73; day 7: 7.3 ± 0.94 versus 3.7 ± 0.94, P < 0.01; day 14: 11.6 ± 0.51 versus 8.0 ± 1.15, P < 0.01) (Figure 1C).

Simvastatin Promotes Both Angiogenesis and Lymphangiogenesis

Wound angiogenesis was analyzed by immunostaining of an endothelial cell–specific marker, CD31, in 10-μm frozen sections to visualize neovascularization. Figure 2A shows neovascularization at the margin in simvastatin- or vehicle-treated wounds in diabetic mice on day 14. A few small vessels were seen at the wound margin in the vehicle-treated group, whereas large numbers of vessels were growing toward the center of the wound in the

Figure 2. Effects of simvastatin on vascularity in granulation tissues at the wound margin in db/db mice. A: Neovascularization at the wound margin in simvastatin- or vehicle-treated diabetic mice after 14 days. Original magnification, ×100. Scale bar = 100 μm. Green and blue fluorescence corresponds to CD31-positive newly formed blood vessels and DAPI-labeled nuclei, respectively. B: Percentage of vascularity, quantified as described in Materials and Methods. *P < 0.001 versus vehicle (n = 5 in each group).

Figure 3. Effects of simvastatin on lymphangiogenesis in granulation tissues at the wound margin in db/db mice. A: Lymphangiogenesis at the wound margin in simvastatin- or vehicle-treated diabetic mice after 14 days. Original magnification, ×100. Scale bar = 100 μm. Green and blue fluorescence corresponds to LYVE-1-positive newly formed lymphatic vessels and DAPI-labeled nuclei, respectively. B: Percentage of lymphatic vascularity, quantified as described in Materials and Methods. *P < 0.001 versus vehicle (n = 5 in each group).
Simvastatin group. Simvastatin significantly enhanced wound vascularity based on image analysis of the percentage of the fluorescent area (9.29% ± 1.29% versus 3.25% ± 1.33%; P < 0.001) (Figure 2B). Wound lymphangiogenesis was analyzed by immunostaining of a LEC-specific marker, LYVE-1, in 10-μm frozen sections. Figure 3A shows new lymphatic vessels at the margin of simvastatin- or vehicle-treated wounds in diabetic mice on day 14. Wound lymphatic vascularity was significantly enhanced by simvastatin (percentage of fluorescent area: 1.72% ± 0.460% versus 0.395% ± 0.260%; P < 0.001) (Figure 3B). New vessels and lymphatics in granulation tissue in both groups were not covered with α-smooth muscle actin–positive mural cells (see Supplemental Figure S1 at http://ajp.amjpathol.org).

Simvastatin Induces Capillary Morphogenesis of LECs and Has an Antiapoptotic Effect but Does Not Induce Proliferation

To characterize the effects of simvastatin on lymphangiogenesis, we performed a chord formation assay in primary human LECs in vitro. Treatment with simvastatin promoted LEC chord formation in a dose-dependent manner (Figure 4A). This effect was significantly blocked by the PI3 kinase inhibitor LY294002, the mTOR inhibitor rapamycin, and the PI3/mTOR inhibitor wortmannin-rapamycin (P < 0.05) (Figure 4C). The proliferative and antiapoptotic effects of simvastatin on LECs were also examined because these are major effects of simvastatin in vascular endothelial cells. Simvastatin did not promote LEC proliferation, even at higher concentrations, and seemed to be slightly cytotoxic at 10^{-12} mol/L and 10^{-10} mol/L (Figure 5A). However, simvastatin treatment resulted in significant inhibition of H_{2}O_{2}-induced apoptosis compared with controls (Figure 5B).

Simvastatin Promotes Macrophage Infiltration and VEGF-C Production in Wounds

The number of macrophages in granulation tissues was evaluated in wounds on day 7. This timing was chosen because reepithelialization was almost complete on day 14 in simvastatin-treated wounds, and inflammatory cells had already diminished. The number of macrophages in simvastatin-treated wounds on day 7 was significantly...
greater than that in controls (Figure 6, A and B). Most of the macrophages in the simvastatin-treated group expressed the M2 marker, IL-13, rather than the M1 marker, TNF-α, whereas most macrophages in the vehicle-treated group expressed TNF-α rather than IL-13 (Figure 6, C–F). The macrophages in the simvastatin-treated group produced VEGF-C (Figure 7A), and VEGF-C expression was significantly up-regulated in simvastatin-treated wounds compared with controls (Figure 7B).

Other proangiogenic mediators in wound granulation tissue were evaluated by real-time PCR. Platelet-derived growth factor β, endothelial nitric oxide synthase, and fibroblast growth factor 2 were significantly up-regulated by simvastatin stimulation (see Supplemental Figure S2 at http://ajp.amjpathol.org).

**Discussion**

In this study, we found that topical application of simvastatin accelerated diabetic wound healing via promotion of angiogenesis and lymphangiogenesis. Many studies have reported that statins, including simvastatin, have strong angiogenic effects on vascular endothelial cells or placental stem cells and that these effects are mainly mediated by the PI3-kinase/Akt pathway, although we note that other findings have also been reported.

Consistent with these reports, abundant neovascularization and proangiogenic growth factors were observed in wounds treated with topical simvastatin in our in vivo study. Statins were originally introduced as systemic antihyperlipidemic drugs; however, a recent study has shown the value of topical simvastatin. An advantage of topical application is that a suitable concentration of simvastatin can be applied without a risk of serious systemic adverse effects, such as rhabdomyolysis. Our results suggest that topical application of simvastatin could be a
new therapeutic strategy for treatment of local ischemic conditions, such as those in patients with diabetic ulcers.

Lymphangiogenesis is a major factor in diabetic refractory wound healing. Therefore, we focused on the effects of simvastatin on wound lymphangiogenesis. Recent studies have suggested that several biological functions of LECs are partially regulated by the AKT/PI3K/mTOR pathway. Consistent with these observations, capillary morphogenesis of LECs was significantly stimulated by simvastatin as an effect on vascular endothelial cells that was, at least in part, regulated by the AKT/PI3K/mTOR pathway.

Our results suggest that the mechanisms underlying the lymphangiogenic effects of simvastatin in LECs might be similar to those for angiogenic effects. These mechanisms include antiapoptosis and promotion of capillary morphogenesis because LECs develop from a vascular network in an embryonic stage, and these cells have a similar lineage. However, contrary to our expectation, simvastatin did not promote proliferation of LECs in vitro. During the wound healing process, new lymphatics are formed in newly generated granulation tissue, indicating that proliferation of pre-existing lymphatic vessels is needed.

Because simvastatin did not promote the proliferation of LECs, we evaluated other possible sources of lymphangiogenic factors. Several reports suggest that infiltrating macrophages contribute to lymphangiogenesis as the major producer of VEGF-C in cutaneous wound healing, and therefore we evaluated the effects of simvastatin on macrophages. Macrophages carry VEGF receptor 3, in addition to producing VEGF-C, and thus act as both autocrine and paracrine factors. We have previously reported that healing impairment in diabetes involves reduced lymphangiogenesis and suppressed macrophage function, such as recruitment to inflammatory sites and secretion of growth factors. In this study, the number of infiltrating macrophages in granulation tissue was significantly increased by topical application of simvastatin, and most of these macrophages produced VEGF-C. These observations suggest that simvastatin recovers lymphangiogenic function that is impaired in macrophages under diabetic conditions.

Increased apoptosis is a major concern in wound healing in a diabetic state. Hyperglycemia induces proinflammatory cytokines, such as TNF-α, and oxidative stress, which result in increased apoptosis in diabetes. Our study found that most infiltrating macrophages in diabetic wounds had an M1 proinflammatory phenotype producing abundant TNF-α. Simvastatin decreased H2O2-induced apoptosis in LECs in vitro and increased M2 anti-inflammatory phenotype macrophages in granulation tissue in vivo. We suggest that this anti-apoptotic effect of simvastatin also plays an important role, in addition to promotion of angiogenesis and lymphangiogenesis.

Increased infiltration of macrophages induced by simvastatin may have further benefits because the histologic scores of diabetic wounds were significantly improved by topical application of simvastatin. The histologic score reflects the degree of maturation of granulation tissue, including inflammation, collagen deposition, and reepithelialization, in addition to neovascularization. Macrophages play a central role in all stages of wound healing and orchestrate the wound healing process by exerting proinflammatory functions and facilitating wound healing during the early stage and stimulating proliferation of fibroblasts, keratinocytes, and endothelial cells in the proliferative stage. Because the main focus of this study was lymphangiogenesis, we did not investigate the effects of simvastatin on reepithelialization or formation of extracellular matrix. This will require further experiments in a future study.

In conclusion, regulation of apoptosis and capillary differentiation are essential for development of functional lymphatics during wound healing. The findings of the present study suggest that topical simvastatin can stimulate lympho-
hangiogenesis directly and indirectly via stimulation of macrophages. Vascular remodeling induced by simvastatin might have therapeutic potential in patients with microvascular dysfunction, such as that in diabetic foot ulcer, a major cause of morbidity in the growing population of patients with diabetes. A future investigation is warranted to determine the potential clinical utility of this approach.

References


2224 Asai et al

AJP December 2012, Vol. 181, No. 6